AlphaYou
Overview
Smart money at a glance
Filings to Sep 26, 2026Net selling: insiders sold $3.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$3.4M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 25- Open
- $805.23
- 52-wk high
- $859.34
- High
- $813.53
- 52-wk low
- $538.24
- Low
- $790.02
- Prev close
- $803.90
- Mkt cap
- $81.95B
- P/E
- 19.8x
- Volume
- 721.1K
- Fwd P/E
- 14.5x
- Beta
- 0.19
- Div yield
- 0.45%
- P/S
- 5.3x
- P/B
- 2.6x
- Profit margin
- +27.9%
- Op margin
- +33.1%
- ROE
- +14.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about REGN filings
Are insiders buying or selling Regeneron Pharmaceuticals Inc (REGN) stock?
Net selling: insiders sold $3.4M and bought $0 of REGN stock on the open market in the 90 days to Sep 26, 2026, according to SEC Form 4 filings. $3.4M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was McCourt, Marion (EVP Commercial), who sold $2M. The latest filing was on Sep 3, 2026.
Which members of Congress have traded REGN recently?
None. No member of Congress disclosed a REGN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this REGN smart-money data?
This summary uses filings available on Sep 26, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- MI
Millennium
$142.9M
added
- QR
Qube Research
$73.8M
added
- MI
Millennium
$54.5M
added
What insiders are doing
What Congress is doing
Buys (1)
How top traders are positioned
No tracked top-trader positions in REGN right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 56.6% above what analysts expected.
Earnings per share
$8.00 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
Reports Oct 27, 2026, in 31 days
EPS expected
$14.53 to $17.68
Revenue expected
18 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.75B | $3.88B | $3.61B | $4.29B |
| Cost of what it sold | $521.6M | $584.6M | $669.4M | $576.5M |
| Gross profit | $3.23B | $3.30B | $2.94B | $3.71B |
| What it spent | ||||
| Research and development | $1.56B | $1.63B | $1.65B | $1.63B |
| Sales and admin | $657.8M | $775.0M | $647.7M | $662.1M |
| Total operating expenses | $2.21B | $2.42B | $2.29B | $2.29B |
| What was left | ||||
| Operating profit | $1.03B | $879.9M | $642.9M | $1.42B |
| Interest on debt | $19.3M | $12.2M | $12.9M | $11.0M |
| Profit before tax | $1.76B | $1.04B | $831.2M | $1.53B |
| Tax | $303.3M | $199.1M | $104.0M | $230.9M |
| Net profit | $1.46B | $844.6M | $727.2M | $1.30B |
| EBITDA | $1.92B | $1.20B | $967.3M | $1.66B |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Tone of tracked coverage
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
NeutralSep 24Merck remigromig meets BRUNELLO vision endpoint
NeutralSep 24Regeneron Pharmaceuticals (REGN) Could Be 4% Undervalued Following Class Action Filing
Leans bearishSep 23Regeneron Pharmaceuticals, Inc. (REGN) latest stock news and headlines
NeutralSep 23Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
NeutralSep 23Vertex Pharmaceuticals Incorporated (VRTX) Options Chain - Yahoo Finance
NeutralSep 23State Street Corp Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN
BullishSep 23Regeneron Pharmaceuticals stock trades near its yearly high
BullishSep 23